Filtros de búsqueda

Lista de obras de Albert Oriol

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.

artículo científico publicado en 2016

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

artículo científico publicado en 2013

A new prognostic score for AIDS-related lymphomas in the rituximab-era

artículo científico publicado en 2014

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.

artículo científico

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

artículo científico publicado en 2016

A step forward in therapy for ALL in infants

scientific article published on 01 July 2007

Acute lymphoblastic leukemia in adolescents and young adults.

artículo científico publicado en 2009

Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.

artículo científico publicado en 2007

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

artículo científico publicado en 2017

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

artículo científico publicado en 2013

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

artículo científico publicado en 2012

An RCT of Rapid Genomic Sequencing among Seriously Ill Infants Results in High Clinical Utility, Changes in Management, and Low Perceived Harm

artículo científico publicado en 2020

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

artículo científico publicado en 2016

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

artículo científico publicado en 2017

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

artículo científico publicado en 2011

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

artículo científico publicado en 2017

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

artículo científico publicado en 2014

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

scientific article published on 13 June 2006

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

artículo científico publicado en 2008

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

scientific article published on 01 October 2019

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

artículo científico publicado en 2010

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

scientific article published on 05 February 2014

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

artículo científico publicado en 2010

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

artículo científico publicado en 2017

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

artículo científico publicado en 2016

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

artículo científico publicado en 2017

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.

artículo científico publicado en 2016

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

artículo científico publicado en 2017

Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis

artículo científico publicado en 2006

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

artículo científico publicado en 2012

Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison

artículo científico publicado en 2017

Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia

article

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

artículo científico publicado en 2011

Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial

scientific article published on 01 January 2007

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

artículo científico publicado en 2020

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

artículo científico publicado en 2008

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

article

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

artículo científico publicado en 2009

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

artículo científico publicado en 2013

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

artículo científico publicado en 2015

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

artículo científico publicado en 2016

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

scientific article published on 21 May 2019

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

scientific article published on 03 November 2020

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

artículo científico publicado en 2018

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

artículo científico publicado en 2017

Differentiation stage of myeloma plasma cells: biological and clinical significance.

artículo científico publicado en 2016

Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).

artículo científico publicado en 2013

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients

artículo científico publicado en 2014

Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study.

artículo científico publicado en 2014

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

artículo científico publicado en 2020

Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience

artículo científico publicado en 2012

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2016

Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

scholarly article by B Paiva et al published October 2013 in Leukemia

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

artículo científico publicado en 2013

Extramedullary plasmacytomas in the context of multiple myeloma

artículo científico publicado en 2011

Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older

scientific article published on 16 March 2015

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group

artículo científico publicado en 2015

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

artículo científico publicado en 2014

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

artículo científico publicado en 2016

High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.

artículo científico publicado en 2008

High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.

artículo científico publicado en 2008

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2011

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

artículo científico publicado en 2016

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

artículo científico publicado en 2015

Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma.

artículo científico publicado en 2017

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

artículo científico publicado en 2015

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

scientific article published on 05 August 2016

Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy

scientific article published on 01 March 2003

Increased serum levels of CD44s and CD44v6 in patients with AIDS-related non-Hodgkin's lymphoma

scientific article published on 01 July 2000

International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients ⬇️

artículo científico publicado el 1 de junio de 1998

Invasive aspergillosis in a patient with idiopathic thrombocytopenic purpura without underlying lung disease

artículo científico publicado en 1992

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

artículo científico publicado en 2020

Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols

artículo científico publicado en 2012

Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology ⬇️

artículo científico publicado el 1 de marzo de 1998

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

artículo científico publicado en 2014

Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

artículo científico publicado en 2011

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

artículo científico publicado en 2016

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

artículo científico publicado en 2022

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.

artículo científico publicado en 2016

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial

artículo científico publicado en 2017

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

artículo científico publicado en 2012

Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomas.

artículo científico publicado en 2009

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

artículo científico publicado en 2016

Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome

artículo científico publicado en 2007

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2012

Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials

article

Multiple myeloma with extramedullary disease.

artículo científico publicado en 2011

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

artículo científico publicado en 2017

Neutropenic enterocolitis in adult patients with acute leukemia or stem cell transplant recipients: study of 7 cases

artículo científico publicado en 2007

New drugs in the treatment of multiple myeloma

artículo científico publicado en 2013

Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation.

artículo científico publicado en 2004

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

artículo científico publicado en 2011

Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience.

artículo científico publicado en 2007

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

artículo científico publicado en 2016

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

artículo científico publicado en 2015

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

artículo científico publicado en 2015

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

artículo científico publicado en 2020

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

artículo científico publicado en 2016

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2015

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

artículo científico publicado en 2007

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

artículo científico publicado en 2010

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia

artículo científico publicado en 2013

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

artículo científico publicado en 2016

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

artículo científico publicado en 2014

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

artículo científico publicado en 2016

Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study

artículo científico publicado en 2011

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

artículo científico publicado en 2013

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.

artículo científico publicado en 2016

Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.

artículo científico publicado en 2013

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

artículo científico publicado en 2014

Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.

artículo científico publicado en 2002

Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

artículo científico publicado en 2006

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

scientific article published on 22 April 2019

SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

artículo científico publicado en 2012

Saccharomyces cerevisiae septicemia in a patient with myelodysplastic syndrome

scientific article published on 01 August 1993

Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.

artículo científico publicado en 2007

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

artículo científico publicado en 2016

Second neoplasms in adult patients submitted to haematopoietic stem cell transplantation.

artículo científico publicado en 2017

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

scientific article published on 23 October 2015

Serum pepsinogen I: an early marker of pernicious anemia in patients with type 1 diabetes

artículo científico publicado en 2005

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

scientific article published on 03 July 2019

Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia

artículo científico publicado en 2002

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study ⬇️

artículo científico publicado el 12 de julio de 2012

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

artículo científico publicado en 2014

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.

artículo científico publicado en 2013

Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the P

artículo científico publicado en 2014

Treatment of relapsed or refractory acute lymphoblastic leukemia in adult patients

scientific article published on 23 August 2014

Usefulness and reproducibility of cytomorphologic evaluations to differentiate myeloma from monoclonal gammopathies of unknown significance.

artículo científico publicado en 2001

Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma

artículo científico publicado en 2014

Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients

artículo científico publicado en 2005

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

artículo científico publicado en 2015

[Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia]

scientific article published on 01 September 2005

[Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]

artículo científico publicado en 2006

Bacteriemia por Lactobacillus spp. en un paciente con neutropenia secundaria al tratamiento de una leucemia aguda ⬇️

artículo científico publicado el 8 de diciembre de 2001

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda